Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 5—May 2021

Clinical Laboratory Perspective on Streptococcus halichoeri, an Unusual Nonhemolytic, Lancefield Group B Streptococcus Causing Human Infections

Salika M. Shakir1Comments to Author , Rahul Gill1, Jonathan Salberg, E. Susan Slechta, Mark Feldman, Thomas Fritsche, Jill Clarridge, Susan E. Sharp, and Mark A. Fisher
Author affiliations: University of Utah/ARUP Laboratories, Salt Lake City, Utah, USA (S.M. Shakir, M.A. Fisher); Texas Health Presbyterian Hospital of Dallas, Dallas, Texas, USA (R. Gill, M. Feldman); Kaiser Permanente Regional Microbiology and Molecular Infectious Diseases Laboratories, Portland, Oregon, USA (J. Salberg, S.E. Sharp); ARUP Institute for Clinical and Experimental Pathology, Salt Lake City (E.S. Slechta); Marshfield Clinic Health System, Marshfield, Wisconsin, USA (T. Fritsche); University of Washington, Seattle, Washington, USA (J. Clarridge); Copan Diagnostics, Murrieta, California, USA (S.E. Sharp)

Main Article

Table 2

Antimicrobial susceptibility profiles for 22 human clinical isolates of Streptococcus halichoeri, United States*

Antimicrobial agent MIC values, µg/mL
% Susceptible Range MIC50 MIC90
CRO 100 ≤0.06–0.25 0.12 0.25
CLI 77.3 ≤0.03 to ≥4 0.03 ≥4
DAP 100 ≤0.12–0.5 0.25 0.25
DOX† NA‡ ≤0.25–16 0.25 0.5
ERY 72.7 ≤0.12 to ≥8 0.12 2
LVX 100 ≤0.25–2 1 1
LZD 100 0.5–1 1 1
MEM 100 ≤0.06–0.25 0.06 0.06
PEN 100 ≤0.03–0.06 0.03 0.03
Q/D‡ 94.7 ≤0.25 to ≥4 0.25 0.25
VAN 100 ≤0.5–1 0.5 0.5

*CLI, clindamycin; CRO, ceftriaxone; DAP, daptomycin; DOX, doxycycline; ERY, erythromycin; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIC50, MIC value at which ≥50% of the isolates in a test population are inhibited; MIC90, MIC value at which ≥90% of the isolates in a test population are inhibited; NA, not available; PEN, penicillin; Q/D, quinupristin/dalfopristin; VAN, vancomycin.
†Clinical and Laboratory Standards Institute interpretive breakpoints for doxycycline were not available for viridans group Streptococcus spp. If
breakpoints for S. pneumoniae were applied, 82% would be susceptible (5).
‡n = 19 isolates.

Main Article

1These authors contributed equally to this article.

Page created: March 15, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.